Mitsubishi UFJ Asset Management Co. Ltd. Has $231,000 Stock Position in Xencor, Inc. $XNCR

Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 153.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 29,371 shares of the biopharmaceutical company’s stock after purchasing an additional 17,773 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Xencor were worth $231,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. CWM LLC grew its holdings in Xencor by 195.5% in the first quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 2,231 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Xencor in the 1st quarter valued at about $528,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Xencor in the 1st quarter valued at about $135,000. XTX Topco Ltd increased its position in Xencor by 191.7% in the 1st quarter. XTX Topco Ltd now owns 54,209 shares of the biopharmaceutical company’s stock valued at $577,000 after buying an additional 35,627 shares in the last quarter. Finally, US Bancorp DE raised its stake in Xencor by 312.0% during the 1st quarter. US Bancorp DE now owns 10,432 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 7,900 shares during the period.

Analyst Upgrades and Downgrades

XNCR has been the subject of several recent research reports. Cantor Fitzgerald boosted their price objective on Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. decreased their price target on shares of Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. Wells Fargo & Company dropped their price objective on shares of Xencor from $33.00 to $27.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. Royal Bank Of Canada boosted their target price on shares of Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Bank of America cut shares of Xencor from a “buy” rating to a “neutral” rating and dropped their price target for the company from $23.00 to $12.00 in a research report on Wednesday, September 3rd. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $24.63.

Xencor Stock Performance

Shares of XNCR stock opened at $14.93 on Friday. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -6.22 and a beta of 0.99. Xencor, Inc. has a 52-week low of $6.92 and a 52-week high of $27.24. The company has a 50-day simple moving average of $12.31 and a two-hundred day simple moving average of $9.81.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.64. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The business had revenue of $21.00 million for the quarter, compared to analyst estimates of $29.73 million. During the same period last year, the company posted ($0.71) earnings per share. Xencor’s quarterly revenue was up 18.0% compared to the same quarter last year. On average, sell-side analysts forecast that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.